Novo Nordisk expects continued competition from copycat versions of its blockbuster Wegovy obesity drug this year and could ...

Novo Nordisk cautioned on Wednesday that it expects continued competition this year from copycat versions of its Wegovy ...

Second-quarter sales of the blockbuster drug soared 67% on year, despite millions of U.S. patients using generic unbranded ...

Novo Nordisk is to cut costs as the Wegovy-maker battles competition from rival Eli Lilly and copycat versions of its obesity ...

Sales of Novo Nordisk's blockbuster Wegovy obesity drug rose 67% in the second quarter despite continued competition from ...

Novo Nordisk CFO Karsten Munk Knudsen tells Yahoo Finance the company understands the pressure it is under to deliver better ...

Sales of Wegovy, launched locally in June, more than doubled to 5,000 units or 70 million rupees ($798,230) in July, the data ...

Novo Nordisk (NVO) said Wednesday it will cut costs as it faces increasing competition from Eli Lilly (LLY) and generic versions of its obesity drug Wegovy, with slower growth expected for its ...

Compounding pharmacies are crimping sales of Novo Nordisk's obesity drug Wegovy by making what are essentially copies of the ...

Novo Nordisk faces a critical phase with its obesity drug Wegovy as it confronts competition from Eli Lilly and potential job ...

Novo Nordisk, the Danish drugmaker behind the popular obesity drug Wegovy, warns of fierce competition and market pressures, potentially leading to layoffs. As compounders produce cheaper copycats, U.

If the NDC on your product is different from what’s discussed below, you can confirm it with the manufacturer, Novo Nordisk, at 1-800-727-6500. Wegovy 0.25 mg dose pen (light green label) ...